Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

FDA accepts IND for phase III study of Glypromate

Feb. 2, 2007

Cellzome research program with OrthoMcNeil extended

Feb. 2, 2007

New therapeutic agents for neurological disorders reported in recent patent literature

Feb. 2, 2007

Javelin plans path to NDA filing for intranasal ketamine

Feb. 1, 2007

AV-101 shows potential for neuropathic pain in preclinical studies

Feb. 1, 2007

Tyrima begins clinical testing for depression and anxiety

Feb. 1, 2007

LX-6171 begins phase Ib study for cognitive impairment

Feb. 1, 2007

Galanin antagonist effective against depression-like behavior in rats

Feb. 1, 2007

RPI-78M begins phase IIb study in adrenomyeloneuropathy

Jan. 31, 2007

Targeting orexin receptors may be useful to treat sleep disorders

Jan. 31, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...